X-linked ichthyosis (XLI) is a relatively common keratinization disorder which is caused, in the vast majority of cases, by a total deletion of the sulfatase steroid (STS) gene. Dystrophic epidermolysis bullosa (DEB) is a scarring form of epidermolysis bullosa of either autosomal recessive or dominant inheritance secondary to collagen VII gene mutations. We report the first case of a patient with both XLI and DEB in whom a partial deletion of the STS gene and a recessive point mutation in COL7A1 were demonstrated.

Keywords:
X-linked ichthyosis, Epidermolysis bullosa, Genodermatoses
1.
Nomura K, Nakano H, Umeki K, Harada K, Kon A, Tamai K, et al: A study of the steroid sulfatase gene in families with X-linked ichthyosis using polymerase chain reaction. Acta Derm Venereol 1995;75:340–342.
2.
Sugawara T, Iwaki M, Fujimoto S: Diagnosis of a deletion of steroid sulfatase by polymerase chain reaction and high-performance liquid chromatography. Clin Chim Acta 1997;263:25–32.
3.
Aviram-Goldring A, Goldman B, Netanelov-Shapira I, Chen-Shtoyerman R, Zvulunov A, Tal O, et al: Deletion patterns of the STS gene and flanking sequences in Israeli X-linked ichthyosis patients and carriers: analysis by polymerase chain reaction and fluorescence in situ hybridization techniques. Int J Dermatol 2000;39:182–187.
4.
Christiano AM, Hoffman GG, Zhang X, Xu Y, Tamai Y, Greenspan DS, et al: Strategy for identification of sequence variants in COL7A1 and a novel 2-bp deletion mutation in recessive dystrophic epidermolysis bullosa. Hum Mutat 1997;10:408–414.
5.
Gardella R, Barlati S, Zoppi N, Tadini G, Colombi M: A –96C–>T mutation in the promoter of the collagen type VII gene (COL7A1) abolishing transcription in a patient affected by recessive dystrophic epidermolysis bullosa. Hum Mutat 2000;16:275.
6.
Williams ML: Epidermal lipids and scaling diseases of the skin. Semin Dermatol 1992;11:169–175.
7.
Hernandez-Martin A, Gonzalez-Sarmiento R, De Unamuno P: X-linked ichthyosis: an update. Br J Dermatol 1999;141:617–627.
8.
Yen PH, Marsh B, Allen E, Tsai SP, Ellison J, Connolly L, et al: The human X-linked steroid sulfatase gene and a Y-encoded pseudogene: evidence for an inversion of the Y chromosome during primate evolution. Cell 1988;55:1123–1135.
9.
Ballabio A, Ranier JE, Chamberlain JS, Zollo M, Caskey CT: Screening for steroid sulfatase (STS) gene deletions by multiplex DNA amplification. Hum Genet 1990;84:571–573.
10.
Ballabio A, Carrozzo R, Parenti G, Gil A, Zollo M, Persico MG, et al: Molecular heterogeneity of steroid sulfatase deficiency: a multicenter study on 57 unrelated patients, at DNA and protein levels. Genomics 1989;4:36–40.
11.
Bonifas JM, Morley BJ, Oakey RE, Kan YW, Epstein EH Jr: Cloning of a cDNA for steroid sulfatase: frequent occurrence of gene deletions in patients with recessive X chromosome-linked ichthyosis. Proc Natl Acad Sci USA 1987;84:9248–9251.
12.
Shapiro LJ, Yen P, Pomerantz D, Martin E, Rolewic L, Mohandas T: Molecular studies of deletions at the human steroid sulfatase locus. Proc Natl Acad Sci USA 1989;86:8477–8481.
13.
Yen PH, Marsh B, Allen E, Tsai SP, Ellison J, Connolly L, et al: The human X-linked steroid sulfatase gene and a Y-encoded pseudogene: evidence for an inversion of the Y chromosome during primate evolution. Cell 1988;55:1123–1135.
14.
Alperin ES, Shapiro LJ: Characterization of point mutations in patients with X-linked ichthyosis: effects on the structure and function of the steroid sulfatase protein. J Biol Chem 1997;272:20756–20763.
15.
Basler E, Grompe M, Parenti G, Yates J, Ballabio A: Identification of point mutations in the steroid sulfatase gene of three patients with X-linked ichthyosis. Am J Hum Genet 1992;50:483–491.
16.
Gonzalez-Huerta LM, Messina-Baas OM, Toral-Lopez J, Rivera-Vega MR, Kofman-Alfaro S, Cuevas-Covarrubias SA: Point mutation in the STS gene in a severely affected patient with X-linked recessive ichthyosis. Acta Derm Venereol 2006;86:78–79.
17.
Steuhl KP, Anton-Lamprecht I, Arnold ML, Thiel HJ: Recurrent bilateral corneal erosions due to an association of epidermolysis bullosa simplex Köbner and X-linked ichthyosis with steroid sulfatase deficiency. Graefes Arch Clin Exp Ophthalmol 1988;226:216–223.
18.
Burgeson RE: Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J Invest Dermatol 1993;101:252–255.
19.
Christiano AM, Greenspan DS, Lee S, Uitto J: Cloning of human type VII collagen: complete primary sequence of the alpha 1(VII) chain and identification of intragenic polymorphisms. J Biol Chem 1994;269:20256–20262.
20.
Christiano AM, Hoffman GG, Chung-Honet LC, Lee S, Cheng W, Uitto J, et al: Structural organization of the human type VII collagen gene (COL7A1), composed of more exons than any previously characterized gene. Genomics 1994;21:169–179.
21.
Hashimoto I, Kon A, Tamai K, Uitto J: Diagnostic dilemma of ‘sporadic’ cases of dystrophic epidermolysis bullosa: a new dominant or mitis recessive mutation? Exp Dermatol 1999;8:140–142.
22.
Jarvikallio A, Pulkkinen L, Uitto J: Molecular basis of dystrophic epidermolysis bullosa: mutations in the type VII collagen gene (COL7A1). Hum Mutat 1997;10:338–347.
23.
Uitto J, Christiano AM: Molecular basis for the dystrophic forms of epidermolysis bullosa: mutations in the type VII collagen gene. Arch Dermatol Res 1994;287:16–22.
24.
Gardella R, Zoppi N, Zambruno G, Barlati S, Colombi M: Different phenotypes in recessive dystrophic epidermolysis bullosa patients sharing the same mutation in compound heterozygosity with two novel mutations in the type VII collagen gene. Br J Dermatol 2002;147:450–457.
25.
Mellerio JE, Salas-Alanis JC, Talamantes ML, Horn H, Tidman MJ, Ashton GH, et al: A recurrent glycine substitution mutation, G2043R, in the type VII collagen gene (COL7A1) in dominant dystrophic epidermolysis bullosa. Br J Dermatol 1998;139:730–737.
26.
Hashimoto I, Kon A, Tamai K, Uitto J: Diagnostic dilemma of ‘sporadic’ cases of dystrophic epidermolysis bullosa: a new dominant or mitis recessive mutation? Exp Dermatol 1999;8:140–142.
27.
Hovnanian A, Rochat A, Bodemer C, Petit E, Rivers CA, Prost C, et al: Characterization of 18 new mutations in COL7A1 in recessive dystrophic epidermolysis bullosa provides evidence for distinct molecular mechanisms underlying defective anchoring fibril formation. Am J Hum Genet 1997;61:599–610.
28.
Kern JS, Kohlhase J, Bruckner-Tuderman L, Has C: Expanding the COL7A1 mutation database: novel and recurrent mutations and unusual genotype-phenotype constellations in 41 patients with dystrophic epidermolysis bullosa. J Invest Dermatol 2006;126:1006–1012.
29.
Couttet P, Grange T: Premature termination codons enhance mRNA decapping in human cells. Nucleic Acids Res 2004;32:488–494.
30.
Dang N, Murrell DF: Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa. Exp Dermatol 2008;17:553–568.
31.
Escámez MJ, Garcia M, Cuadrado-Corrales N, Llames S, Charlesworth, de Luca N, et al: The first COL7A1 mutation survey in a large Spanish Dystrophic Epidermolysis Bullosa cohort: c.6527insC disclosed as an unusually recurrent mutation. Br J Dermatol 2010, E-pub ahead of print.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.